The effect of ingaron on the dynamics of copies of deoxyribonucleic acid Epstein - Barr virus in saliva samples and on the manifestation of clinical

Abstract

A total of 60 patients (38 women and 22 men, 36,54±2,14 years old) with a Epstein - Barr infection were examined. The patients were divided into two groups depending on the treatment regimen: 1 group - 34 patients received ingaron therapy (10 intramuscular injections of 500000 units every other day); group 2-26 patients received valcyte (450 mg 2 times a day, by mouth, 2 months) + ingaron at the same dosage. One month after the end of antiviral therapy in the1st group, negative results of half-chain reaction were obtained only in 29,41% of patients. The combination of valcyte and ingaron in patients of the 2nd group was different and differed in the duration of the injection of ingarone: 2a group: ingaron10 injections of 500000 IU intramuscularly every other day; 2b group: ingaron 20 injections of 500000 IU intramuscularly every other day; 2c group: ingaron 10 injections of 500000 IU and 15 injections of 100000 IU intramuscularly every other day. The best result after the introduction of ingaron was obtained in 90% of patients who received the longest course of ingaron in the form of 20 injections of 500000 IU every other day in combination with valcyte. In the other groups, where the total dose of ingaron was lower, positive results were found in 60 and 66,7% of patients. A significant positive change in the number of copies of deoxyribonucleic acid Epstein - Barr virus was found in samples of saliva and the severity of clinical complaints in patients one month after the ingaron monotherapy or combination therapy (valcyte and ingaron) was completed. The best effect of treatment with ingaron is achieved in patients with chronic Epstein - Barr infection with the prolonged introduction of ingaron (at least 20 injections).